https://www.biospace.com/intellia-therapeutics-announces-first-quarter-2024-financial-results-and-highlights-recent-company-progress
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company...
May 10, 2024 - Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, reported...
2024 financial resultsintellia therapeuticsfirst quarter
https://menafn.com/1111060303/Intellia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635C4
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4). CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics,...
intellia therapeutics
https://www.macrotrends.net/stocks/charts/NTLA/intellia-therapeutics/return-on-tangible-equity
Intellia Therapeutics Return on Tangible Equity 2015-2025 | NTLA | MacroTrends
Current and historical return on tangible equity values for Intellia Therapeutics (NTLA) over the last 10 years. Return on tangible equity can be defined as...
return on tangible equityintellia therapeutics20152025ntla
https://www.macrotrends.net/stocks/charts/NTLA/intellia-therapeutics/cash-on-hand
Intellia Therapeutics Cash on Hand 2015-2025 | NTLA | MacroTrends
Intellia Therapeutics cash on hand from 2015 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn...
cash on handintellia therapeutics20152025ntla
https://investingnews.com/intellia-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates/
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business...
Feb 26, 2026 - HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027...
2025 financial resultsintellia therapeuticsfourth quarter
https://www.benzinga.com/insights/analyst-ratings/25/02/44038654/what-analysts-are-saying-about-intellia-therapeutics-stock
What Analysts Are Saying About Intellia Therapeutics Stock - Intellia Therapeutics (NASDAQ:NTLA) -...
intellia therapeuticsanalystssayingstocknasdaq
https://www.globenewswire.com/news-release/2025/03/26/3049528/0/en/Intellia-Therapeutics-Announces-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-Nexiguran-Ziclumeran-nex-z-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosi.html
Intellia Therapeutics Announces FDA Regenerative Medicine
CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
intellia therapeuticsannouncesfdaregenerativemedicine
https://www.fool.com/earnings/call-transcripts/2019/08/01/intellia-therapeutics-inc-ntla-q2-2019-earnings-ca.aspx
Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript | The Motley Fool
Aug 1, 2019 - NTLA earnings call for the period ending June 30, 2019.
earnings call transcriptintellia therapeuticsq2 2019
https://robinhood.com/us/en/stocks/NTLA/
Intellia Therapeutics: NTLA Stock Price Quote & News | Robinhood
View the real-time NTLA price chart on Robinhood and decide if you want to buy or sell commission-free. Other fees such as trading (non-commission) fees, Gold...
intellia therapeuticsstock pricentlaquotenews
https://www.globenewswire.com/news-release/2020/11/09/2122648/0/en/Intellia-Therapeutics-Doses-First-Patient-in-Landmark-CRISPR-Cas9-Clinical-Trial-of-NTLA-2001-for-the-Treatment-of-Transthyretin-Amyloidosis.html
Intellia Therapeutics Doses First Patient in Landmark
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression First-ever in vivo CRISPR treatment delivered intravenously to...
intellia therapeuticsdosesfirstpatientlandmark
https://www.globenewswire.com/news-release/2023/08/03/2717889/0/en/Intellia-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html
Intellia Therapeutics Announces Second Quarter 2023
Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) Plans to initiate a global...
intellia therapeuticssecond quarterannounces2023
https://www.home.saxo/fr-be/markets/stocks/ntla-xnas
Intellia Therapeutics Inc. action | Saxo Bank
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics.
intellia therapeuticsincactionsaxobank
https://investingnews.com/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-2674831361/
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | INN
Dec 27, 2025 - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today...
intellia therapeuticsreportsinducementgrants
https://www.home.saxo/nb-no/markets/stocks/ntla-xnas
Intellia Therapeutics Inc. aksje | Saxo Bank
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics.
intellia therapeuticsincaksjesaxobank
https://menafn.com/1109346690/ROSEN-A-RANKED-AND-LEADING-FIRM-Encourages-Intellia-Therapeutics-Inc-Investors-To-Secure-Counsel-Before-Important-Deadline-In-Securities-Class-Action-NTLA
ROSEN, A RANKED AND LEADING FIRM, Encourages Intellia Therapeutics, Inc. Investors To Secure...
ROSEN, A RANKED AND LEADING FIRM, Encourages Intellia Therapeutics, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action NTLA....
https://www.biospace.com/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-jun-01-2020
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Jun 01, 2020 - BioSpace
Jun 2, 2020 - Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex...
https://www.financialcontent.com/article/bizwire-2025-2-17-ntla-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-that-intellia-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc....
investor alert
https://www.marketscreener.com/news/transcript-intellia-therapeutics-inc-presents-at-44th-annual-j-p-morgan-healthcare-conference-ce7e58d9d88af727
Transcript : Intellia Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference,...
Jan 14, 2026 - Presenter SpeechLut Ming Cheng Good morning. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the...
https://www.biospace.com/intellia-therapeutics-presents-new-preclinical-data-supporting-its-crispr-cas9-engineered-tcr-t-cell-treatment-for-acute-myeloid-leukemia-at-the-62nd-ash-annual-meeting
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T...
Dec 7, 2020 - Lead immuno-oncology development candidate NTLA-5001shows high anti-tumor activity as promising cancer treatmentin proof-of-concept mouse models of acute...
https://www.fool.com/investing/2018/04/13/why-intellia-therapeutics-inc-stock-lost-192-in-ma.aspx
Why Intellia Therapeutics, Inc. Stock Lost 19.2% in March | The Motley Fool
Apr 13, 2018 - The gene-editing company's stock hit a lifetime high last month but sold off on weaker-than-expected earnings results.
https://investingnews.com/intellia-therapeutics-announces-fda-lift-of-clinical-hold-on-magnitude-2-phase-3-clinical-trial-in-attrv-pn/
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in...
Jan 27, 2026 - Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM Intellia...
https://www.biospace.com/intellia-therapeutics-to-present-updated-data-from-ongoing-phase-1-study-of-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-and-hold-conference-call-to-discuss-third-quarter-2023-earnings-in-november
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the...
Oct 26, 2023 - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging...
https://www.prnewswire.com/news-releases/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302384219.html
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with...
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia...
https://www.prnewswire.com/news-releases/ntla-investors-have-opportunity-to-lead-intellia-therapeutics-inc-securities-fraud-lawsuit-302383784.html
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of...
https://www.prnewswire.com/news-releases/intellia-therapeutics-inc-sued-for-securities-law-violations--investors-should-contact-the-gross-law-firm-for-more-information--ntla-302382416.html
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross...
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased...
https://www.biospace.com/intellia-therapeutics-announces-proposed-public-offering-of-common-stock-nov-30-2020
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Nov 30, 2020 - BioSpace
Dec 1, 2020 - Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex...